C-O7HAmitochondrial transplantation, mitochondrial augmentation, biomarkers
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Alongside partners MitoAction, MitoCanada, Northwell Health, Cure Mito Foundation, and CureARS, Countdown For A Cure is proud to collaborate in keeping our community informed, engaged, and connected to the science, people, and progress shaping mitochondrial medicine. Noa Sher, Ph.D., Chief Scientific Officer at Minovia Therapeutics and a member of Countdown For A Cure’s Scientific & Medical Advisory Board, is part of a growing global community shaping what’s next in mitochondrial science. She envisions a future where mitochondrial augmentation becomes a standardized therapeutic approach, supporting everything from organ transplantation to chronic and age-related conditions. Across the mitochondrial field, researchers, clinicians, advocates, and organizations are working together to build the tools needed to move this science forward. By restoring mitochondrial function, this collective work is not just studying cellular energy; it is opening new pathways for treating rare disease, ca
Discover the groundbreaking potential of hematopoietic stem cells to tackle mitochondrial dysfunction in this eye-opening talk by Dr. Noa Sher from Minovia. Northwell Health is New York State’s largest health care provider and private employer, with 21 hospitals, about 900 outpatient facilities and more than 12,000 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 87,000 employees – 18,900 nurses and 4,900 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 10
Myelodysplastic syndromes (MDS) are a group of bone marrow failures that occur when the blood-forming cells in the bone marrow become abnormal leading to an abnormal differentiation and production of one or more blood cell types. According to the American Cancer Society, in the United States, MDS occurs at a rate of 4.8 cases for every 100,000 people; MDS affects an estimated 60,000 persons in the United States, with 10,000-15,000 new cases recorded each year. MDS is defined by ineffective haematopoiesis resulting in blood cytopenias (a reduction in the number of mature blood cells), and clonal instability with a risk of evolution to acute myeloid leukaemia (AML). Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML. MDS is generally a disease that develops with ageing; the median age at diagnosis of MDS is \~70 years, and patients frequently have comorbid conditions. The goals of therapy for patients with MDS are to reduce disease-associated symptoms and the risk of disease progression and death, thereby improving both quality and quantity of life. Minovia Therapeutics Ltd. ("Minovia") is a biotech company developing novel therapeutics based on its mitochondrial augmentation technology (MAT). MNV-201 is a cell therapy produced by MAT that consists of the participant's autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) enriched with allogeneic placental-derived mitochondria, manufactured in Minovia's GMP facility.
Mitochondrial diseases are a genetically diverse group of disorders, some of which are caused by mutations or deletions in the mitochondrial DNA (mtDNA) and which display a wide range of severity and phenotypes. Despite a prevalence of roughly 1 in 8500 in the population there is no effective treatments for the majority of mitochondrial diseases beyond supportive care (Gorman 2016, Elliott 2008). Many of these, such as Pearson syndrome and Kearns-Sayre syndrome, are early onset disorders, and may lead to mortality within the first decades of life. Importantly, mitochondria are selectively inherited from the mother. In addition, there are numerous diseases in which mitochondrial dysfunction plays an important role. Some examples are Alzheimer's and Parkinson's disease, both of which are known to have mitochondrial involvement. Minovia therapeutics develops a therapeutic intervention called mitochondrial augmentation technology (MAT). For the development work, Minovia needs patients' cells with different mutations that will allow to study the baseline heteroplasmy and functionality of patient hematopoietic cells, identify potential biomarkers to assess mitochondrial content and function in liquid biopsies, and study the efficacy of MAT in different PMDs.
Primary Mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by mutations in genes encoded by nuclear Deoxyribonucleic Acid (DNA) or by mutations and/or deletions in the mitochondrial DNA (mtDNA). While some mitochondrial disorders only affect a single organ (e.g., the eye in Leber hereditary optic neuropathy \[LHON\]), many involve multiple organs. Mitochondrial disorders may present at any age and a frequent feature is the increasing number of organs involved in the course of the disease. Minovia Therapeutics Ltd. ("Minovia") is a biotech company developing novel therapeutics based on its mitochondrial augmentation technology (MAT). MNV-201 is a cell therapy produced by MAT that consists of the participant's autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) enriched with allogeneic placental-derived mitochondria, manufactured in Minovia's GMP facility.
The study Objective is to collect samples of bone marrow aspirates and peripheral blood of patients with MDS for use in non-clinical research to investigate mitochondrial function sequence and effect of mitochondrial augmentation.
The study objectives are to evaluate the safety of a single intravenous (IV) infusion of autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria in participant with primary mitochondrial disease associated with mitochondrial DNA mutations or deletions. 6 participants aged from 4 to 18 years old on the day of screening visit with primary mitochondrial disease associated with mitochondrial DNA mutations or deletions will be enrolled.
Pharmaseed Ltd and BIOHOUSE GROUP hosted the seminar "Cell Therapy- From Proof of Concept to Clinical Trial" on 23.11.2021 The lectures were given in English by key researchers in cell therapy companies in Israel and USA. Shai Melcer | BIOHOUSE- [email protected] Galit Gincberg | Pharmaseed [email protected] Chaya Mazouz | Orgenesis- [email protected] Uri Herzberg | Cabaletta Bio- [email protected] Nisim Perets | ItayAndBiond- [email protected] Natalie Yivgi-Ohana | Minovia- [email protected] Hadar Sarig | Pharmaseed Ltd.- [email protected]
UMDF Power Surge 2020: Friday, June 26, 2020 - Clinical/Scientific/Family Session Clinical Trial Updates Speakers: Joanne Quan, MD, Modis/Zogenix; Tolga Uz, MD, PhD, Astellas Pharma; Chad Glasser, PharmD, MPH, Cyclerion; and Alex Dorenbaum, MD, Reneo Pharmaceutical; Michio Hirano, MD, Columbia University, New York, NY (Entrada Therapeutics MNGIE Natural History Study Lead Investigator); Magnus Hansson, MD, PhD, Abliva (formerly NeuroVive); Matthew Klein, MD, PhD, PTC Therapeutics; Noa Sher, PhD, Minovia Therapeutics; Magali Taiel, MD, Gensight-Biologics; Peter W. Stacpoole, PhD, MD, University of Florida, Gainesville, FL; and Fernando Scaglia, MD, Baylor College of Medicine, Houston, TX
Mitochondrial diseases are a genetically heterogeneous group of disorders caused by mutations or deletions in mitochondrial DNA (mtDNA) displaying a wide range of severity and phenotypes. These diseases may be inherited from the mother (mitochondrial inheritance) or non-inherited. The latter are ultra-rare pediatric diseases caused by a mutation or deletion of mtDNA, which develop into a systemic multi organ disease and eventually death. MNV-BM-BLD is a therapeutic process for enrichment of patient's peripheral hematopoietic stem cells with normal and healthy mitochondria derived from donor blood cells. The process, called mitochondria augmentation therapy, aims to reduce the symptoms of mitochondrial diseases.
Placenta will be collected and from these, mitochondrial will be harvested. Mitochondria will be used in mitochondrial augmentation therapy.
Minovia Therapeutics Announces Interim Data from Phase 2 --> Accessibility: Skip TopNav Consumer Products and Services News Automobiles and Parts News Food & Beverage News Home Goods & Construction News Leisure Goods News Media & Entertainment News Personal Care News Retail News Travel and Leisure News Energy News Alternative Energy News Oil Gas and Coal News Chemicals News Banks & Financial Services News Banking News Closed-End Investments News Finance and Credit Services News Investment Banking and Brokerage Services News Insurance News Real Estate & REITs News Healthcare … eractions, potential eligibility for priority review, and the opportunity for a rolling submission of a future Biologics License Application (BLA) for MNV-201. Concurrently, Rare Pediatric Disease Designation (RPD) is granted to drugs which are under development for rare childhood diseases and provides the Company with the potential to receive a pediatric priority review voucher (PRV) if the drug is initially approved for that rare childhood disease. A PRV grants the holder a … od disease. A PRV grants the holder an expedited six-month review of a new drug application. PRVs are tradeable and have historically commanded prices in excess of US$100 million; however, PRV programs are currently on hold awaiting reauthorization by Congress. The Company also recently announced entry into a definitive business combination agreement (the “Business Combination Agreement”) with Launch One Acquisition Corp. (Nasdaq: LPAA, “Launch One”), a publicly traded specia
Countdown For A Cure Raises Over $1 Million at 2026 Evening of Energy Gala | GlobeNewswire by notified Hjem Følg innhold Våre kunder Om tjenesten Bli kunde Countdown For A Cure Raises Over $1 Million at 2026 Evening of Energy Gala 24.2.2026 18:57:08 CET | GlobeNewswire by notified | Press release Share Raising funds to advance high-impact mitochondrial research with applications across rare disease, neurodegeneration, and healthspan A Media Snippet accompanying this announcement is available by clicking on this link. ATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Countdown For A Cure (CFAC) hosted … During the program, CFAC presented its highest honor, the Countdown For A Cure Award, to Douglas C. Wallace, PhD, Director of the Center for Mitochondrial & Epigenomic Medicine at Children’s Hospital of Philadelphia. Widely regarded as the father of mitochondrial medicine, Dr. Wallace was recognized for pioneering discoveries that established the role of mitochondria in human health, disease, and aging. The 2026 Powerhouse Award was presented to Sonya Knebel, 2022 Europe … Natalie Yivgi-Ohana, PhD, Founder and CEO of Minovia Therapeutics and 2025 CFAC grant recipient. Through its 2025 grant, CFAC is specifically supporting mitochondrial biomarker development, advancing tools to measure cellular function, track disease progression, and assess therapeutic response with greater precision. This work is critical to accelerating clinical translation and evaluating next-generation mitochondrial therapies. The program blended science and storytelling, … lling, with a live performance by Izabela Rose and an after-party led by Grammy Award-winning producer DJ Babey Drew. The 2026 Evening of Energy was made possible through the support of sponsors, including InPrime Legal and MoveDocs. “In science, Mitzi and Jeff are solving for the root cause,” said Jonathan Page, Founder of InPrime Legal. “They are building the foundation for the future of health.” Funds raised will support CFAC’s expanding research pipeline and education ini … C’s expanding research pipeline and education initiatives, with additional 2026 grant announcements planned this spring. “Disease moves quickly. To truly change lives, we have to move faster,” said Co-Founders Mitzi and Jeff Solomon. “Our third annual Evening of Energy reflects a powerful truth: when a community unites around bold science, progre
Global Genes - Natalie Yivgi Ohana, co-founder and CEO of... Facebook Вход Публикация Global Genes Global Genes 22 июль 2019 г. · Поделился/-ась с Доступно всем Natalie Yivgi Ohana, co-founder and CEO of Minovia Therapeutics, discusses how mitochondria augmentation therapy may help treat more common conditions in a recent #RARECast . globalgenes.org Using Cell Therapies to Restore Power in Mitochondrial Diseases - Global Genes Все реакции: 8 2 комментария Поставить "Нравится" Комментировать Самые актуальные Jayne Salisbury I wasnt really able to hear and understand clearly this recor
Minovia Therapeutics Mitochondrial Augmentation Technology --> Accessibility: Skip TopNav Consumer Products and Services News Automobiles and Parts News Food & Beverage News Home Goods & Construction News Leisure Goods News Media & Entertainment News Personal Care News Retail News Travel and Leisure News Energy News Alternative Energy News Oil Gas and Coal News Chemicals News Banks & Financial Services News Banking News Closed-End Investments News Finance and Credit Services News Investment Banking and Brokerage Services News Insurance News Real Estate & REITs News Healthca
Minovia kicks off first mitochondrial cell therapy trial + | Bioworld | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 lands
Instagram Instagram Log In Sign Up Close Never miss a post from minoviatx Sign up for Instagram to stay in the loop. Sign up Log in minoviatx • Follow More options minoviatx 37w Last month, Dr. Natalie Yivgi-Ohana, Co-founder and Chief Executive Officer of Minovia Therapeutics, participated in the Aging Research & Drug Discovery Meeting 2025 (ARDD) held at the University of Copenhagen. We extend our sincere appreciation to the organizers for curating a highly distinguished program and for convening leading experts in the field. The conference addressed critical topics related to the hall … : “You cannot change what cannot be measured.” Minovia was recently awarded a grant by the Countdown for a Cure Foundation to further progress mitochondrial biomarker development in the context of both disease and aging, a critical step in deepening scientific understanding and therapeutic potential in this area. The University of Copenhagen provided a remarkable setting for this important gathering, underscoring both the rich history and promising future of aging researc
FDA grants IND clearance for Minovia’s Phase Ib MDS therapy trial Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & … has granted clearance for Minovia Therapeutics’ investigational new drug (IND) application to commence a Phase Ib trial of MNV-201 for low-risk myelodysplastic syndrome (MDS). The dose exploration, open-label trial will explore the safety and efficacy of various dosages of MNV-201 in individuals diagnosed with low-risk MDS. Go deeper with GlobalData Reports LOA and PTSR Model - Minnelide in Gastric Cancer Reports LOA and PTSR Model - Navtemadlin in Chronic Idiopathic Myelofi
Facebook Познакомьтесь с тем, что вам нравится . Войдите на Facebook Электронный адрес или номер мобильного телефона Пароль Войти Забыли пароль? Создать новый аккаунт Русский English (UK) Українська Suomi 中文(简体) Deutsch العربية Другие языки... Зарегистрироваться Вход Messenger Facebook Lite Видео Meta Pay Магазин Meta Meta Quest Ray-Ban Meta Meta AI Instagram Threads Политика конфиденциальности Центр конфиденциальности Информация Создать объявление Создать Страницу Разработчикам Вакансии Файлы cookie Рекламные предпочтения Условия использования Справка Загрузка контактов и лица, не являющиеся
Minovia Therapeutics gets FDA Orphan Drug Designation for MNV-201 in MDS | LARVOL posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i
Filing/prosecution in Israel | Classements des cabinets d'avocats et des avocats par The Legal 500 Europe, Middle East & Africa guide Aller au contenu principal The Legal 500 > Europe, Middle East & Africa > Israel > Intellectual property > Filing/prosecution The Legal 500 Europe, Middle East & Africa Asia Pacific Canada Caribbean Deutschland Disputes Services Global Green Guide Latin America Lex Paris United Kingdom - Solicitors United Kingdom - The Bar United States Worldwide Israel Afghanistan Albania Algeria Angola Armenia Austria Azerbaijan Bahrain Belarus Belgium Benin Bosnia … nced Investments The Phoenix Mortgages (Gold) The Phoenix Pension And Provident Fund Ltd Agwa Farm Holmes Place International PLANCK RESOLUTION LTD Dawson Partners Nucleai Ltd. Neema Shefa Israel LTD Madan Technologies A.C.A. Jemes FareFair LTD Zappa Newco (2023) Ltd. Michel Raidman Principaux dossiers Advised Windward on global trade mark portfolio management and filings, including securing registrations in the US, EU, Singapore, and Israel. Advised The Phoenix Group on a mu … rther edge to understanding what the vendable product is when drafting a patent application.’ ‘A professional team with extensive legal knowledge and an exceptionally high level of service.’ Principaux clients Technion Institute of Technology –Technology Transfer office T3. Tel Hashomer Medical Research, Infrastructure & Services -Tech Transfer Sheba Medical Center The Kitchen FoodTech Hub Guerbet PlantArcBio Lumus Minovia ADAMA ICL Israel Ltd. Novella AMG plastech P.C.B. TEC … el and Adina Cohen ' provide timely and relevant advice when navigating complex application procedures ’. Other key practitioners are Lilach Luzzatto Shukrun , whose practice covers patent prosecutions and strategic IP advice; and trade mark prosecution practitioner Shimon Maman . Responsables de la pratique: Kfir Luzzatto; Emanuel Manzurola; Amir Palmery Autres avocats clés: Sarit Ben-Shmuel; Adina Cohen; Lilach Luzzatto Shukrun; Shimon Maman Les références ‘They are profess
#jpm2026 #minovia #mitochondrialmedicine #celltherapy #biotech | Natalie Yivgi-Ohana LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s U
#minovia #jpm2023 #jpmorgan #mitochondria #mitochondrialdisease #business #biotechnology | Minovia Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Mitochondria and Longevity: Insights from Minovia's CEO on Podcast | Minovia Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo … 30 | Faculty @ Yale | Director @ Longevity Clinic | Principal @ Longevity Tech Fund | Creator @ Decoding Longevity Podcast 7mo Edited It was a pleasure to present our work on the “Biological vs Technical reliability of clocks” at Harvard Medical School ’s Biomarkers of Aging Consortium . Our poster focused on the Biological versus Technical Reliability of Epigenetic Clocks and Their Implications for Disease Prognosis and Intervention Response — a topic that sits at the core
Mitochondria and the Future of Health with Natalie Yivgi-Ohana of Minovia - Business Trip | Podcast on Spotify
Dr. Natalie Yivgi-Ohana, Ph.D.... — Progress, Potential, and Possibilities Podcast / Show — Apple Podcasts Поиск Главная Новое Топ-чарты Поиск 26 января 58 мин. Dr. Natalie Yivgi-Ohana, Ph.D. - CEO, Minovia Therapeutics - Harnessing The Therapeutic Power Of Mitochondria Progress, Potential, and Possibilities Podcast / Show Воспроизвести Send us Fan Mail Dr. Natalie Yivgi-Ohana, Ph.D. is Co-Founder and CEO of Minovia Therapeutics ( https://minoviatx.com/ ), a biotech company dedicated to rapidly advance life-changing therapies that address the unmet need of serious and complex mitochondrial dis … ochemistry at The Hebrew University, after which she completed her postdoctoral fellowship at the Weizmann Institute of Science. Dr. Yivgi-Ohana also has her B.Sc., Medical Sciences Ben-Gurion University of the Negev and her Master’s Degree, Human Reproduction Bar-Ilan University. Dr. Yivgi-Ohana founded Minovia with a passion to help children and adults with mitochondrial diseases worldwide. #NatalieYivgiOhana #MinoviaTherapeutics #MitochondrialDysfunction #Mitoc
Countdown For A Cure Collaborates on Mitochondrial Medicine Advancements | Countdown posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig … website: https://lnkd.in/gJuWavAY In this Special Issue, we welcome authors to submit papers on clinical advances in understanding the causes of thromboembolism in cancer, studies on the diagnostic tests that can define thromboembolic risk, and strategies for the prevention and treatment of acute thromboembolism. Submission DDL: 20 September 2026 #Cancer_Associated_Venous_Thromboembolism #Prevention #Treatment 9 Like Comment Share Copy LinkedIn Facebook X To view or add a co … ommunity Health and collaborated with the Kaiser Permanente Northern California Residency and Fellowship Programs and Kaiser Permanente Division of Research to answer this important public health question. Article: https://lnkd.in/gEHDxyX2 Citation: Yap EN, Wei J, Darling C, Linehan E, Behrends M, Ng KP. Erector Spinae Plane versus Pectoralis Nerve Block for Mastectomy in Cancer Patients: A Retrospective, Multicenter Cohort Study. J Pain Res. 2025 Sep 16;18:4775-4785. doi: 10
Expert Series: Two Generations of Mitochondrial Augmentation Technology: Clinical Advances in Treating Primary Mitochondrial Disease - MitoAction Facebook Instagram Twitter Get Support – Call 1-888-MITO-411 Shop Events Donate Search MitoAction Support, Education, Outreach and Advocacy for Children and Adults Living with Mitochondrial Disease Mitochondrial Disease About Mito New Patient Kit Types of Mitochondrial Diseases Symptoms of Mito Treatment for Mito Diagnosing Mito Mito FAQs Mito in the News Diagnosis & Care Mitochondrial Disease Diagnosis Find a Mito Doctor Mito Disease Trea … h Packages Liney’s Lovies MitoAction Programs Dalia’s Wish Matthew Harty Camper Fund & Scholarship Marcel’s Way Family Fund MitoArtisan’s Playtime MitoSantas MyMito App Education Monthly Expert Series Wondering Wednesdays Energy In Action Podcast Energy 4 Education Patient Education Forums International Metabolic Conference Planning & Preparation Health Insurance Disability Benefits Mobility Devices Vehicle Modification Estate Planning Medical Child Abuse Join the Ca … Energy Walks Sandra K. Russell Derby Day Benefit for Mito Matthew Harty Camper Fund Events Team MitoAction! Volunteer Host a MitoSocial Host a MitoPlaydate Create a Fundraiser Become a MitoChampion Share Your Ideas Raise Your Voice Externally Led Patient-Focused Drug Development Meetings Take Legislative Action Mitochondrial Disease Awareness Week Open Mito Mic & Art Show MitoAction Memories About MitoAction Contact Us Connect on Social Our Team Meet Our Partners Newsle
Two Generations of Mitochondri... - MitoAction Expert Series - Apple Podcasts Buscar Inicio Novedades Lo más escuchado Buscar 21 de noviembre de 2025 1 h 5 min Two Generations of Mitochondrial Augmentation Technology: Clinical Advances in Treating Primary Mitochondrial Disease MitoAction Expert Series Reproducir Mitochondrial Augmentation Technology (MAT) involves internalizing healthy, functional mitochondria into patient-derived cells to address mitochondrial dysfunction. Minovia has developed two generations of MAT products, studied in patients with primary mitochondrial disease i
Natalie Yivgi-Ohana on Mitochondrial Transplantation and Biomarkers | Countdown posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … on. Countdown For A Cure is proud to accelerate this biomarker research through grant funding, advancing our mission to deepen understanding of mitochondrial function and cellular energy in health and disease. And thank you to Nathalie Niddam for continuing to elevate important conversations in the fields of longevity and cellular health. Natalie Yivgi-Ohana 2mo It was such an honor to spend time with Nathalie Niddam and talk about the importance of mitochondrial health when … ntdown for a Cure, we are honored to help accelerate biomarker research through grant funding with Minovia Therapeutics —advancing our ability to better measure mitochondrial function and deepen our understanding of cellular energy in health and disease. It’s incredibly exciting to see this research moving forward. I'm grateful to Nathalie Niddam for hosting this thoughtful conversation with Natalie Yivgi-Ohana —CEO of Minovia Therapeutics and a member of CFAC's Scientific an
Mitochondria and the Future of ... – Business Trip – Apple Podcasts Suchen Startseite Neu Top-Charts Suchen 22. Juli 2025 52 Min. Mitochondria and the Future of Health with Natalie Yivgi-Ohana of Minovia Business Trip Wiedergeben Greg and Matias interview Natalie Yivgi-Ohana of Minovia. Natalie is a life science entrepreneur with twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. In this episode, we discuss: How mito
"Are we going to change the world?" asks Natalie Yivgi-Ohana, PhD, CEO of Minovia. An incredible story of courage, of perseverance, of belief in self and others. This one is not to be missed. | mAcademia
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Mitochondria and the Future of Health with Natalie Yivgi-Ohana of Minovia PsyMed Ventures Newsletter Subscribe Sign in Business Trip Episodes Mitochondria and the Future of Health with Natalie Yivgi-Ohana of Minovia Business Trip by PsyMed Ventures, a podcast exploring the future of mental and brain health & the startups building it PsyMed Ventures Jul 22, 2025 1 Share Welcome back to Business Trip by PsyMed Ventures , a podcast exploring the future of mental and brain health & the startups building it! 🧠 Greg and Matias interview Natalie Yivgi-Ohana of Minovia. Natalie is a life scie … ry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. In this episode, we discuss: How mitochondria impacts health by not just regulating energy, but also hormones, cell survival, and overall cellular function. Why mitochondrial dysfunction is a root cause of many conditions, from rare genetic disorders to aging and mental health issues. What mitochondrial therapy does by restoring function
Mitochondria and the Future of… - Business Trip - Apple Podcasts Search Home New Top Charts Search July 22, 2025 52 min Mitochondria and the Future of Health with Natalie Yivgi-Ohana of Minovia Business Trip Play Greg and Matias interview Natalie Yivgi-Ohana of Minovia. Natalie is a life science entrepreneur with twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. In this episode, we discuss: How mitochondria impacts
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Minovia Therapeutics Announces Data from Preclinical Studies Demonstrating that Mitochondrial Augmentation of CD34+ cells Confers Functional Benefit and that Mitochondrial Transfer Occurs Between Hematopoietic Cells In Vivo - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Subm … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Minovia Therapeutics Announces Data from Preclinical Studies Demonstrating that Mitochondrial Augmentation of CD34+ cells Confers Functional Benefit and that Mitochondrial Transfer Occurs Between Hematopoietic Cells In Vivo October 1, 2021 | 4 min read Twitter LinkedIn Facebook Email … bsp;· Jennifer C. Smith-Parker Rare diseases FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug May 27, 2026 · 3 min read · Heather McKenzie BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Ge … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome October 16, 2025 | 13 min read Twitter LinkedIn Facebook Email Print Regulatory Milestone Adds to Fast-Track Designation Providing Further Potential Regulatory Advantages as Company Develops First-in-Class Mi … bsp;· Jennifer C. Smith-Parker Rare diseases FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug May 27, 2026 · 3 min read · Heather McKenzie Vaccines Lilly just bought renowned regulator Peter Marks a pipeline to play with May 27, 2026 · 2 min read · Annalee Armstrong BioSpace is the digital hub for life science news and jobs. We provide essential insights, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome April 3, 2025 | 5 min read Twitter LinkedIn Facebook Email Print MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologou … Drug Administration (FDA) has cleared its second Investigational New Drug (IND) application for MNV-201 , an autologous hematopoietic stem cell product augmented with allogeneic mitochondria . The IND supports the initiation of a Phase I I clinical trial of MNV-201 in pediatric patients with Pearson Syndrome, a primary mitochondrial disease . Based on previous clinical experience from the 1 st generation product, MNV-101 (autologous hematopoietic stem cell product augmented w … bsp;· Jennifer C. Smith-Parker Rare diseases FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug May 27, 2026 · 3 min read · Heather McKenzie Immunology and inflammation Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss May 27, 2026 · 3 min read · Annalee Armstrong BioSpace is the digital hub for life science news and jobs. … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome September 18, 2025 | 12 min read Twitter LinkedIn Facebook Email Print Regulatory Milestone Underscores Continued Promise of First-in-Class Mitochondrial Cell Therapy HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSW … eractions, potential eligibility for priority review, and the opportunity for a rolling submission of a future Biologics License Application (BLA) for MNV-201. The Company also recently announced entry into a definitive business combination agreement (the “Business Combination Agreement”) with Launch One Acquisition Corp. (Nasdaq: LPAA, “Launch One”), a publicly traded special purpose acquisition company. Following the expected closing of the transaction contempla … bsp;· Jennifer C. Smith-Parker Rare diseases FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug May 27, 2026 · 3 min read · Heather McKenzie Vaccines Lilly just bought renowned regulator Peter Marks a pipeline to play with May 27, 2026 · 2 min read · Annalee Armstrong BioSpace is the digital hub for life science news and jobs. We provide essential insights, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Astellas to pay Minovia $20M upfront, with $420M on the table per product, for mitochondrial cell therapies | Fierce Biotech Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fier
New Hope for Rare Mitochondrial Diseases: An Interview With Minovia Therapeutics’ Natalie Yivgi Ohana - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell an … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development New Hope for Rare Mitochondrial Diseases: An Interview With Minovia Therapeutics’ Natalie Yivgi Ohana July 15, 2019 | 6 min read | Mark Terry Twitter LinkedIn Facebook Email Print In late June, Minovia Therapeutics dosed the first patient in a Phase I/II clinical trial wi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases December 21, 2022 | 5 min read Twitter LinkedIn Facebook Email Print Minovia Therapeutics, a clinical-stage global … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers August 28, 2025 | 12 min read Twitter LinkedIn Facebook Email Print HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a c … at age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research proposal related to the development of novel mitochondrial blood-based biomarkers. Minovia Chief Scientific Officer Dr. Noa Sher, commented, “We are grateful to the Countdown for a Cure Foundation, whose funds are expected to be instrumental in our advancing development of blood-based functional mitochondrial biomarkers. These biomarkers will enable i … rs and patients suffering from mitochondrial diseases. The Countdown for a Cure grant will fund clinical operations for blood sample collection from approximately 30 patients with primary mitochondrial diseases, and 140 samples from healthy controls. The samples collected will be analyzed in Minovia’s labs with its newly developed biomarkers, and a “MitoScore” will be determined for each sample. In addition, the Countdown for a Cure funding will support the development of new … CFAC partners with leading research institutions and patient advocacy groups to fund cutting-edge science and provide critical support to families. Mitzi and Jeff are driven by an unwavering commitment to supporting families, accelerating research, and uniting a community determined to make a tangible difference in the lives of those affected by
Minovia Therapeutics Announces Manufacturing Partnership with BioSpherix and Appoints David O’Donnell as Global Head of Manufacturing and Supply Chain - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FD … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Minovia Therapeutics Announces Manufacturing Partnership with BioSpherix and Appoints David O’Donnell as Global Head of Manufacturing and Supply Chain November 23, 2020 | 3 min read Twitter LinkedIn Facebook Email Print Minovia Therapeutics, a clinical-stage company focused on the development … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition November 21, 2025 | 13 min read Twitter LinkedIn Facebook Email Print Results from pre-clinical studies conducted by scientists at Memorial Sloan Kettering C … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busine … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform January 14, 2026 | 12 min read Twitter LinkedIn Facebook Email Print New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based thera … intelligence Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling May 21, 2026 · 3 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newsletters Podcasts Webinars Hotbeds Companies More Events R … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs July 30, 2021 | 6 min read Twitter LinkedIn Facebook Email Print Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., “Minovia”) and Astellas Pharma Inc. (TSE: 4503, Presid … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Home - Minovia Home - Minovia Mission Science Mitochondria Scientific Approach Mitochondrial Augmentation Publications Therapy Patients & Advocacy About Us News Working at Minovia He C S Harnessing the therapeutic power of mitochondria Minovia Therapeutics is the first clinical stage company to use mitochondrial transplantation approach with the hope to bring life changing therapies to people suffering from mitochondrial dysfunction. From rare diseases to aging, Minovia is pioneering mitochondria-based therapies – a science-backed platform for healthier life. Mitochondria Mitochondria are
Minovia Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Minovia Therapeutics Ltd. Holding Company | 2011 | Israel | 10-50 | minovia.com Holding Company | 2011 | Israel | 10-50 | minovia.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Minovia Therapeutics Ltd. is a company based in Tirat Carmel, Israel, that specializes in the development of mitochondrial cell therapies. The compan … apy 01 Sep 2025 · www.globenewswire.com Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers Aug. 27, 2025 -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research prop … rs and patients suffering from mitochondrial diseases. The Countdown for a Cure grant will fund clinical operations for blood sample collection from approximately 30 patients with primary mitochondrial diseases, and 140 samples from healthy controls. The samples collected will be analyzed in Minovia’s labs with its newly developed biomarkers, and a “MitoScore” will be determined for each sample. In addition, the Countdown for a Cure funding will support the development of new … CFAC partners with leading research institutions and patient advocacy groups to fund cutting-edge science and provide critical support to families. Mitzi and Jeff are driven by an unwavering commitment to supporting families, accelerating research, and uniting a community determined to make a tangible difference in the lives of those affected by mitochondrial disease and all diseases connected to mitochondrial dysfunction. Launch One Acquisition Corp. is a company set up to m … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Minovia Therapeutics Ltd. - IVC Data & Insights --> --> Recently Updated Analytics Products & Solutions Reports & Insights Free Trial Buy Log In Remember Me Forgot my password Free Trial Free Content Please wait Processing your login information Cancel You're about to hit a 'session timeout' in 5 minutes. Are you still actively using IVC-Online website? Search Go Advanced Search Advanced Search Did you know? Search at IVC-Online works best with strings or words of 3 letters or more. Please try again Minovia Therapeutics Lt … * New investor Investor Type Amount Remarks abC Defghij Venture Capital Fund abCDe abC Defghij Holding Company abCDe abC Defghij Investment Company abCDe abC Defghij Private Investor abCDe abC Defghij Private Investor abCDe abC Defghij Private Investor abCDe First Round Jan. 01, 2017 R&D abCDe abCDe * New investor Investor Type Amount Remarks abC Defghij Venture Capital Fund abCDe abC Defghij Private Investor abCDe R&D Grants Expand / Colla … sp; R&D Grants Expand / Collapse All Round Date Stage Amount Remarks R&D Grant Aug. 27, 2025 R&D abCDe Granted by Countdown For A Cure (CFAC), a non-profit organization dedicated to advancing mitochondrial research and medicine. Granted by Countdown For A Cure (CFAC), a non-profit organization dedicated to advancing mitochondrial research and medicine. * New investor Investor Type Amount Remarks abC Defghij Other abCDe R&D Grant May. 01, 2024 R&D abCDe &n … tor Investor Type Amount Remarks abC Defghij Government Agency abCDe R&D Grant Jun. 01, 2020 R&D abCDe * New investor Investor Type Amount Remarks abC Defghij Government Agency abCDe Non-Equity Assistance Expand / Collapse All Date Stage Remarks Non-Equity Assistance Feb. 23, 2021 R&D Contributor Type Amount Remarks abC Defghij General Accelerator abCDe Last Updated: abCDe IVC Number: abCDe IVC Research Center 10
Minovia Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Minovia Therapeutics Ltd. Holding Company | 2011 | Israel | 10-50 | minovia.com Holding Company | 2011 | Israel | 10-50 | minovia.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Minovia Therapeutics Ltd. is a company based in Tirat Carmel, Israel, that specializes in the development of mitochondrial cell therapies. The compan … apy 01 Sep 2025 · www.globenewswire.com Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers Aug. 27, 2025 -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research prop … rs and patients suffering from mitochondrial diseases. The Countdown for a Cure grant will fund clinical operations for blood sample collection from approximately 30 patients with primary mitochondrial diseases, and 140 samples from healthy controls. The samples collected will be analyzed in Minovia’s labs with its newly developed biomarkers, and a “MitoScore” will be determined for each sample. In addition, the Countdown for a Cure funding will support the development of new … CFAC partners with leading research institutions and patient advocacy groups to fund cutting-edge science and provide critical support to families. Mitzi and Jeff are driven by an unwavering commitment to supporting families, accelerating research, and uniting a community determined to make a tangible difference in the lives of those affected by mitochondrial disease and all diseases connected to mitochondrial dysfunction. Launch One Acquisition Corp. is a company set up to m … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Minovia Therapeutics - Company Profile Solutions Industries Services Resources About Company Directory > Biotech > Minovia Therapeutics ⚠ Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Minovia Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it. REPORT AN ERROR Minovia Therapeutics ↗ Tirat Carmel, Israel VISIT WEBSITE Minovia Therapeutics is a clinical-stage biotechnology company pioneering the use of mitochondrial cell therapy to tre … Sheba Medical Center (Clinical collaboration), Countdown for a Cure Foundation (Grant/Research partnership) COMPETITION Position : Emerging LEADERSHIP Key Executives: Natalie Yivgi-Ohana - Co-Founder & CEO Noa Sher - Chief Scientific Officer John Cox - Chairman of the Board Scientific Founders : Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson Board Members : John Cox, Maha Radhakrishnan, Ilan Ganot LINKS Website : minoviatx.com LinkedIn : LinkedIn Profile Disclaimer
About Us - Minovia About Us - Minovia Mission Science Mitochondria Scientific Approach Mitochondrial Augmentation Publications Therapy Patients & Advocacy About Us News Working at Minovia He C S Devoted to our commitment Our journey continues to evolve, thanks to constant feedback from our diverse team of experts, who are dedicated to addressing the unmet clinical needs associated with mitochondrial dysfunction Our vision We strive to be a global leader in the development of novel mitochondrial cell therapies to treat people stricken with diseases of mitochondrial dysfunction. Every day, … ry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with a passion to help children and adults with mitochondrial diseases worldwide. Noa Sher, PhD Chief Scientific Officer X Noa Sher, PhD Chief Scientific Officer Noa is highly experienced research leader in the cell therapy space and a molecular and cellular biologist by training. Noa received her PhD in Biochemist … ry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with passion to help children ans adults with mitochondrial diseases worldwide. Ephraim Aharonson, PhD Co-founder & Board Member X Ephraim Aharonson, PhD Co-founder & Board Member Ephraim is an Ex-Deputy Head, Israel Institute for Biological Research. He is a former executive at Siemens Israel and a serial angel in